Article(id=1329527159607112043, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527047069741522, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.05.004, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1709913600000, receivedDateStr=2024-03-09, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794913576269, onlineDateStr=2026-11-17, pubDate=1715270400000, pubDateStr=2024-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794913576269, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794913576269, creator=13701087609, updateTime=1794913576269, updator=13701087609, issue=Issue{id=1329527047069741522, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='5', pageStart='449', pageEnd='566', issueExtLink='null', onlineDate='null', pubDate='1715270400000', pubDateStr='2024-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794913549438, creator='13701087609', updateTime=1794962129197, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329730805833773281, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527047069741522, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329730805833773282, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527047069741522, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=464, endPage=469, ext={EN=ArticleExt(id=1329527159816827244, articleId=1329527159607112043, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on glucocorticoid induced osteoporosis, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Glucocorticoid (GC) is widely used in the treatment of inflammation and immune system diseases, but long-term and high-dose use can cause various drug-related adverse reactions, including GC induced osteoporosis (GIO). Excessive GC can have harmful effects on bone cells, leading to impaired bone formation and resorption. Therefore, all long-term users of GC need to undergo regular fracture risk assessments. The article discussed the pathogenesis, clinical manifestations, fracture risk, and treatment strategies of GIO, to provide some reference for clinical practice.

, authors=Wen LUO, Jing CHEN*, authorsList=Wen LUO, Jing CHEN, authorCompany=null, correspAuthors=Jing CHEN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329527160089457005, articleId=1329527159607112043, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=糖皮质激素诱发骨质疏松研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

糖皮质激素(glucocorticoid,GC)被广泛用于炎症、免疫系统疾病的治疗,但长期、高剂量使用可引发多种药物相关不良反应,其中包括GC诱发的骨质疏松(glucocorticoid induced osteoporosis,GIO)。GC过量可对骨细胞产生有害影响,导致骨形成和骨吸收受损,故所有长期使用GC者需定期接受骨折风险评估。现总结GIO发病机制、临床表现、骨折风险和治疗策略,为临床提供一定参考。

, authors=罗文, 陈静*, authorsList=罗文, 陈静, authorCompany=null, correspAuthors=陈静, authorNote=

罗文,博士研究生,主管药师,研究方向:药理学。

, correspAuthorsNote=
陈静,主任药师,研究方向:药理学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=fH6R2AcNRIfwPj9AsUOixQ==, magXml=wz++ZptHbgfColJV7ZkCHA==, pdfUrl=null, pdf=n50Cl5MIiO70jdqDyPt3uQ==, pdfFileSize=1530650, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=eisyEIkMhPuhxq62lwNxoQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329527160575996276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329527160668270967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160575996276, language=EN, stringName=Wen LUO, firstName=Wen, middleName=null, lastName=LUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527160747962747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160575996276, language=CN, stringName=罗文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000, bio={"content":"

罗文,博士研究生,主管药师,研究方向:药理学。

"}, bioImg=null, bioContent=

罗文,博士研究生,主管药师,研究方向:药理学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527160454361456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, xref=null, ext=[AuthorCompanyExt(id=1329527160462750065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China), AuthorCompanyExt(id=1329527160475332978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000)])]), Author(id=1329527160827654524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329527160915734910, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160827654524, language=EN, stringName=Jing CHEN, firstName=Jing, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527160991232383, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160827654524, language=CN, stringName=陈静, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527160454361456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, xref=null, ext=[AuthorCompanyExt(id=1329527160462750065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China), AuthorCompanyExt(id=1329527160475332978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000)])])], keywords=[Keyword(id=1329527161087701376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=EN, orderNo=1, keyword=glucocorticoid), Keyword(id=1329527161171587457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=EN, orderNo=2, keyword=osteoporosis), Keyword(id=1329527161255473538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=EN, orderNo=3, keyword=osteoblast), Keyword(id=1329527161330971011, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=EN, orderNo=4, keyword=osteoclast), Keyword(id=1329527161410662788, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=EN, orderNo=5, keyword=bone cell), Keyword(id=1329527161498743173, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=CN, orderNo=1, keyword=糖皮质激素), Keyword(id=1329527161628766598, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=CN, orderNo=2, keyword=骨质疏松), Keyword(id=1329527161716846984, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=CN, orderNo=3, keyword=成骨细胞), Keyword(id=1329527163398762890, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=CN, orderNo=4, keyword=破骨细胞), Keyword(id=1329527163541369227, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, language=CN, orderNo=5, keyword=骨细胞)], refs=[Reference(id=1329527163671392652, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions[J]. Expert Opin Pharmacother, 2013, 14(2): 185-197., articleTitle=null, refAbstract=null), Reference(id=1329527163759473037, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Kobza AO, Herman D, Papaioannou A, et al. Understanding and managing corticosteroid-induced osteoporosis[J]. Open Access Rheumatol, 2021, 13: 177-190., articleTitle=null, refAbstract=null), Reference(id=1329527163855942031, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures[J]. J Bone Miner Res, 2000, 15(6): 993-1000., articleTitle=null, refAbstract=null), Reference(id=1329527163935633808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease[J]. N Engl J Med, 2011, 365(1): 62-70., articleTitle=null, refAbstract=null), Reference(id=1329527164011131281, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis[J]. N Engl J Med, 2018, 379(26): 2547-2556., articleTitle=null, refAbstract=null), Reference(id=1329527164086628754, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Wiebe E, Huscher D, Schaumburg D, et al. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease[J]. Ann Rheum Dis, 2022, 81(9): 1313-1322., articleTitle=null, refAbstract=null), Reference(id=1329527164183097747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Hayat S, Magrey MN. Glucocorticoid-induced osteoporosis: insights for the clinician[J]. Cleve Clin J Med, 2020, 87(7): 417-426, articleTitle=null, refAbstract=null), Reference(id=1329527164266983828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Lane NE. Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments[J]. Curr Osteoporos Rep, 2019, 17(1): 1-7., articleTitle=null, refAbstract=null), Reference(id=1329527164346675605, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Hachemi Y, Rapp AE, Picke AK, et al. Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture[J]. J Mol Endocrinol, 2018, 61(1): R75-R90., articleTitle=null, refAbstract=null), Reference(id=1329527164426367382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy[J]. Endocr Rev, 2018, 39(5): 519-548., articleTitle=null, refAbstract=null), Reference(id=1329527164497670551, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang L, Heckmann BL, Yang X, et al. Osteoblast autophagy in glucocorticoid-induced osteoporosis[J]. J Cell Physiol, 2019, 234(4): 3207-3215., articleTitle=null, refAbstract=null), Reference(id=1329527164581556632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids[J]. Mol Cell Biol, 1996, 16(8): 4128-4136., articleTitle=null, refAbstract=null), Reference(id=1329527164652859801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts[J]. Biochem Biophys Res Commun, 2005, 329(1): 177-181., articleTitle=null, refAbstract=null), Reference(id=1329527164745134490, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Ohnaka K, Taniguchi H, Kawate H, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis[J]. Biochem Biophys Res Commun, 2004, 318(1): 259-264., articleTitle=null, refAbstract=null), Reference(id=1329527164866769308, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Almeida M, Han L, Ambrogini E, et al. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts[J]. J Biol Chem, 2011, 286(52): 44326-44335., articleTitle=null, refAbstract=null), Reference(id=1329527164959043998, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Mazziotti G, Formenti AM, Adler RA, et al. Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/vitamin D axes, treatment options and guidelines[J]. Endocrine, 2016, 54(3): 603-611., articleTitle=null, refAbstract=null), Reference(id=1329527165063901599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density[J]. Endocrinology, 2006, 147(12): 5592-5599., articleTitle=null, refAbstract=null), Reference(id=1329527165147787680, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis[J]. Endocrinology, 1999, 140(10): 4382-4389., articleTitle=null, refAbstract=null), Reference(id=1329527165227479457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Angeli A, Dovio A, Sartori ML, et al. Interactions between glucocorticoids and cytokines in the bone microenvironment[J]. Ann NY Acad Sci, 2002, 966: 97-107., articleTitle=null, refAbstract=null), Reference(id=1329527165336531362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Dalle Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis[J]. J Bone Miner Res, 2001, 16(1): 97-103., articleTitle=null, refAbstract=null), Reference(id=1329527165424611748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy[J]. Arthritis Rheum, 2003, 48(11): 3224-3229., articleTitle=null, refAbstract=null), Reference(id=1329527165508497829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis[J]. J Clin Densitom, 2004, 7(4): 359-363., articleTitle=null, refAbstract=null), Reference(id=1329527165583995302, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Chiodini I, Torlontano M, Carnevale V, et al. Skeletal involvement in adult patients with endogenous hypercortisolism[J]. J Endocrinol Invest, 2008, 31(3): 267-276., articleTitle=null, refAbstract=null), Reference(id=1329527165672075687, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Sato AY, Richardson D, Cregor M, et al. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases[J]. Endocrinology, 2017, 158(3): 664-677., articleTitle=null, refAbstract=null), Reference(id=1329527165781127592, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Morelli V, Donadio F, Eller-Vainicher C, et al. Role of glucocorticoid receptor polymorphism in adrenal incidentalomas[J]. Eur J Clin Invest, 2010, 40(9): 803-811., articleTitle=null, refAbstract=null), Reference(id=1329527165885985193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Geusens P. Osteoporosis: clinical features[J]. Minerva Med, 2008, 99(2): 167-175., articleTitle=null, refAbstract=null), Reference(id=1329527165990842794, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review[J]. Osteoporos Int, 2019, 30(6): 1145-1156., articleTitle=null, refAbstract=null), Reference(id=1329527166070534571, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Li Z, Chines AA, Meredith MP. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture[J]. J Musculoskelet Neuronal Interact, 2004, 4(1): 64-74., articleTitle=null, refAbstract=null), Reference(id=1329527166154420652, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Eastell R, Vittinghoff E, Lui LY, et al. Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project[J]. J Bone Miner Res, 2022, 37(1): 29-35., articleTitle=null, refAbstract=null), Reference(id=1329527167777616301, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Laurent MR, Goemaere S, Verroken C, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the belgian bone club[J]. Front Endocrinol, 2022, 13: 908727., articleTitle=null, refAbstract=null), Reference(id=1329527167953777070, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Messina OD, Vidal M, Torres J, et al. Evidence based Latin American guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: this manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF)[J]. Aging Clin Exp Res, 2022, 34(11): 2591-2602., articleTitle=null, refAbstract=null), Reference(id=1329527168037663152, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk[J]. J Bone Miner Res, 2004, 19(6): 893-899., articleTitle=null, refAbstract=null), Reference(id=1329527168142520754, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology[J]. Ann Rheum Dis, 2002, 61(8): 718-722., articleTitle=null, refAbstract=null), Reference(id=1329527168234795443, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Compston J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis[J]. Clin Endocrinol, 2011, 74(5): 547-550., articleTitle=null, refAbstract=null), Reference(id=1329527168322875828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Compston J. Glucocorticoid-induced osteoporosis: an update[J]. Endocrine, 2018, 61(1): 7-16., articleTitle=null, refAbstract=null), Reference(id=1329527168406761909, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis[J]. Arthritis Rheumatol, 2017, 69(8): 1521-1537., articleTitle=null, refAbstract=null), Reference(id=1329527168490647990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis[J]. Arch Osteoporos, 2017, 12(1): 43., articleTitle=null, refAbstract=null), Reference(id=1329527168561951159, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial[J]. Lancet, 2009, 373(9671): 1253-1263., articleTitle=null, refAbstract=null), Reference(id=1329527168624865720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study[J]. Lancet Diabetes Endocrinol, 2018, 6(6): 445-454., articleTitle=null, refAbstract=null), Reference(id=1329527168708751801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases[J]. J Bone Miner Res, 2017, 32(6): 1291-1296., articleTitle=null, refAbstract=null), Reference(id=1329527168780054970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS[J]. J Clin Endocrinol Metab, 2020, doi: 10.1210/clinem/dgaa756., articleTitle=null, refAbstract=null), Reference(id=1329527168880718267, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Anastasilakis AD, Makras P, Yavropoulou MP, et al. Denosumab discontinuation and the rebound phenomenon: a narrative review[J]. J Clin Med, 2021, 10(1): 152., articleTitle=null, refAbstract=null), Reference(id=1329527168981381564, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial[J]. Ann Rheum Dis, 2011, 70(5): 778-784., articleTitle=null, refAbstract=null), Reference(id=1329527169065267645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis[J]. J Rheumatol, 2010, 37(1): 141-148., articleTitle=null, refAbstract=null), Reference(id=1329527169144959422, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu ZM, Zhang M, Zong Y, et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: a meta-analysis and systematic review of randomized controlled trials[J]. PLoS One, 2022, 17(5): e0267706., articleTitle=null, refAbstract=null), Reference(id=1329527169237234111, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial[J]. J Bone Miner Res, 2013, 28(6): 1355-1368., articleTitle=null, refAbstract=null), Reference(id=1329527169337897408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Brent MB, Thomsen JS, Brüel A. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice[J]. Sci Rep, 2021, 11(1): 12258., articleTitle=null, refAbstract=null), Reference(id=1329527169438560705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Chandler H, Brooks DJ, Hattersley G, et al. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia[J]. Osteoporos Int, 2019, 30(8): 1607-1616., articleTitle=null, refAbstract=null), Reference(id=1329527169514058178, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Leder BZ, O'Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis[J]. J Clin Endocrinol Metab, 2015, 100(2): 697-706., articleTitle=null, refAbstract=null), Reference(id=1329527169597944259, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Kobayakawa T, Miyazaki A, Kanayama Y, et al. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration[J]. Mod Rheumatol, 2023, 33(1): 96-103., articleTitle=null, refAbstract=null), Reference(id=1329527169681830340, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Anastasilakis AD, Tsourdi E, Makras P, et al. Bone disease following solid organ transplantation: a narrative review and recommendations for management from the European Calcified Tissue Society[J]. Bone, 2019, 127: 401-418., articleTitle=null, refAbstract=null), Reference(id=1329527169757327813, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial[J]. Arthritis Rheum, 2009, 60(11): 3346-3355., articleTitle=null, refAbstract=null), Reference(id=1329527169832825286, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis[J]. Osteoporos Int, 2012, 23(12): 2769-2774., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329527160454361456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, xref=null, ext=[AuthorCompanyExt(id=1329527160462750065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China), AuthorCompanyExt(id=1329527160475332978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.05.004, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.05.004, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.05.004, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.05.004, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1715270400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
糖皮质激素诱发骨质疏松研究进展
罗文 , 陈静 *
世界临床药物 | 医药专论 2024,45(5): 464-469
收起
收藏切换
世界临床药物 |医药专论 2024 , 45 (5) : 464 -469
糖皮质激素诱发骨质疏松研究进展
全屏
[Author(id=1329527160575996276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329527160668270967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160575996276, language=EN, stringName=Wen LUO, firstName=Wen, middleName=null, lastName=LUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527160747962747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160575996276, language=CN, stringName=罗文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000, bio={"content":"

罗文,博士研究生,主管药师,研究方向:药理学。

"}, bioImg=null, bioContent=

罗文,博士研究生,主管药师,研究方向:药理学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527160454361456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, xref=null, ext=[AuthorCompanyExt(id=1329527160462750065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China), AuthorCompanyExt(id=1329527160475332978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000)])]), Author(id=1329527160827654524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329527160915734910, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160827654524, language=EN, stringName=Jing CHEN, firstName=Jing, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527160991232383, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, authorId=1329527160827654524, language=CN, stringName=陈静, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527160454361456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, xref=null, ext=[AuthorCompanyExt(id=1329527160462750065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China), AuthorCompanyExt(id=1329527160475332978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527159607112043, companyId=1329527160454361456, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000)])])]
罗文, 陈静*
作者信息
  • 绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000
通讯作者:
陈静,主任药师,研究方向:药理学。
作者简介:

罗文,博士研究生,主管药师,研究方向:药理学。

Research progress on glucocorticoid induced osteoporosis
Wen LUO, Jing CHEN*
Affiliations
  • Department of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang 621000, Sichuan Province, China
出版时间: 2024-05-10 doi: 10.13683/j.wph.2024.05.004
文章导航
收藏切换

糖皮质激素(glucocorticoid,GC)被广泛用于炎症、免疫系统疾病的治疗,但长期、高剂量使用可引发多种药物相关不良反应,其中包括GC诱发的骨质疏松(glucocorticoid induced osteoporosis,GIO)。GC过量可对骨细胞产生有害影响,导致骨形成和骨吸收受损,故所有长期使用GC者需定期接受骨折风险评估。现总结GIO发病机制、临床表现、骨折风险和治疗策略,为临床提供一定参考。

糖皮质激素  /  骨质疏松  /  成骨细胞  /  破骨细胞  /  骨细胞

Glucocorticoid (GC) is widely used in the treatment of inflammation and immune system diseases, but long-term and high-dose use can cause various drug-related adverse reactions, including GC induced osteoporosis (GIO). Excessive GC can have harmful effects on bone cells, leading to impaired bone formation and resorption. Therefore, all long-term users of GC need to undergo regular fracture risk assessments. The article discussed the pathogenesis, clinical manifestations, fracture risk, and treatment strategies of GIO, to provide some reference for clinical practice.

glucocorticoid  /  osteoporosis  /  osteoblast  /  osteoclast  /  bone cell
罗文, 陈静. 糖皮质激素诱发骨质疏松研究进展. 世界临床药物, 2024 , 45 (5) : 464 -469 . DOI: 10.13683/j.wph.2024.05.004
Wen LUO, Jing CHEN. Research progress on glucocorticoid induced osteoporosis[J]. World Clinical Drug, 2024 , 45 (5) : 464 -469 . DOI: 10.13683/j.wph.2024.05.004

参考文献 引证文献
排序方式:
[1]
Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions[J]. Expert Opin Pharmacother, 2013, 14(2): 185-197.
[2]
Kobza AO, Herman D, Papaioannou A, et al. Understanding and managing corticosteroid-induced osteoporosis[J]. Open Access Rheumatol, 2021, 13: 177-190.
[3]
Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures[J]. J Bone Miner Res, 2000, 15(6): 993-1000.
[4]
Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease[J]. N Engl J Med, 2011, 365(1): 62-70.
[5]
Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis[J]. N Engl J Med, 2018, 379(26): 2547-2556.
[6]
Wiebe E, Huscher D, Schaumburg D, et al. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease[J]. Ann Rheum Dis, 2022, 81(9): 1313-1322.
[7]
Hayat S, Magrey MN. Glucocorticoid-induced osteoporosis: insights for the clinician[J]. Cleve Clin J Med, 2020, 87(7): 417-426
[8]
Lane NE. Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments[J]. Curr Osteoporos Rep, 2019, 17(1): 1-7.
[9]
Hachemi Y, Rapp AE, Picke AK, et al. Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture[J]. J Mol Endocrinol, 2018, 61(1): R75-R90.
[10]
Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy[J]. Endocr Rev, 2018, 39(5): 519-548.
[11]
Wang L, Heckmann BL, Yang X, et al. Osteoblast autophagy in glucocorticoid-induced osteoporosis[J]. J Cell Physiol, 2019, 234(4): 3207-3215.
[12]
Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids[J]. Mol Cell Biol, 1996, 16(8): 4128-4136.
[13]
Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts[J]. Biochem Biophys Res Commun, 2005, 329(1): 177-181.
[14]
Ohnaka K, Taniguchi H, Kawate H, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis[J]. Biochem Biophys Res Commun, 2004, 318(1): 259-264.
[15]
Almeida M, Han L, Ambrogini E, et al. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts[J]. J Biol Chem, 2011, 286(52): 44326-44335.
[16]
Mazziotti G, Formenti AM, Adler RA, et al. Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/vitamin D axes, treatment options and guidelines[J]. Endocrine, 2016, 54(3): 603-611.
[17]
Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density[J]. Endocrinology, 2006, 147(12): 5592-5599.
[18]
Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis[J]. Endocrinology, 1999, 140(10): 4382-4389.
[19]
Angeli A, Dovio A, Sartori ML, et al. Interactions between glucocorticoids and cytokines in the bone microenvironment[J]. Ann NY Acad Sci, 2002, 966: 97-107.
[20]
Dalle Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis[J]. J Bone Miner Res, 2001, 16(1): 97-103.
[21]
Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy[J]. Arthritis Rheum, 2003, 48(11): 3224-3229.
[22]
Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis[J]. J Clin Densitom, 2004, 7(4): 359-363.
[23]
Chiodini I, Torlontano M, Carnevale V, et al. Skeletal involvement in adult patients with endogenous hypercortisolism[J]. J Endocrinol Invest, 2008, 31(3): 267-276.
[24]
Sato AY, Richardson D, Cregor M, et al. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases[J]. Endocrinology, 2017, 158(3): 664-677.
[25]
Morelli V, Donadio F, Eller-Vainicher C, et al. Role of glucocorticoid receptor polymorphism in adrenal incidentalomas[J]. Eur J Clin Invest, 2010, 40(9): 803-811.
[26]
Geusens P. Osteoporosis: clinical features[J]. Minerva Med, 2008, 99(2): 167-175.
[27]
Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review[J]. Osteoporos Int, 2019, 30(6): 1145-1156.
[28]
Li Z, Chines AA, Meredith MP. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture[J]. J Musculoskelet Neuronal Interact, 2004, 4(1): 64-74.
[29]
Eastell R, Vittinghoff E, Lui LY, et al. Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project[J]. J Bone Miner Res, 2022, 37(1): 29-35.
[30]
Laurent MR, Goemaere S, Verroken C, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the belgian bone club[J]. Front Endocrinol, 2022, 13: 908727.
[31]
Messina OD, Vidal M, Torres J, et al. Evidence based Latin American guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: this manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF)[J]. Aging Clin Exp Res, 2022, 34(11): 2591-2602.
[32]
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk[J]. J Bone Miner Res, 2004, 19(6): 893-899.
[33]
Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology[J]. Ann Rheum Dis, 2002, 61(8): 718-722.
[34]
Compston J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis[J]. Clin Endocrinol, 2011, 74(5): 547-550.
[35]
Compston J. Glucocorticoid-induced osteoporosis: an update[J]. Endocrine, 2018, 61(1): 7-16.
[36]
Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis[J]. Arthritis Rheumatol, 2017, 69(8): 1521-1537.
[37]
Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis[J]. Arch Osteoporos, 2017, 12(1): 43.
[38]
Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial[J]. Lancet, 2009, 373(9671): 1253-1263.
[39]
Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study[J]. Lancet Diabetes Endocrinol, 2018, 6(6): 445-454.
[40]
Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases[J]. J Bone Miner Res, 2017, 32(6): 1291-1296.
[41]
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS[J]. J Clin Endocrinol Metab, 2020, doi: 10.1210/clinem/dgaa756.
[42]
Anastasilakis AD, Makras P, Yavropoulou MP, et al. Denosumab discontinuation and the rebound phenomenon: a narrative review[J]. J Clin Med, 2021, 10(1): 152.
[43]
Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial[J]. Ann Rheum Dis, 2011, 70(5): 778-784.
[44]
Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis[J]. J Rheumatol, 2010, 37(1): 141-148.
[45]
Liu ZM, Zhang M, Zong Y, et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: a meta-analysis and systematic review of randomized controlled trials[J]. PLoS One, 2022, 17(5): e0267706.
[46]
Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial[J]. J Bone Miner Res, 2013, 28(6): 1355-1368.
[47]
Brent MB, Thomsen JS, Brüel A. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice[J]. Sci Rep, 2021, 11(1): 12258.
[48]
Chandler H, Brooks DJ, Hattersley G, et al. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia[J]. Osteoporos Int, 2019, 30(8): 1607-1616.
[49]
Leder BZ, O'Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis[J]. J Clin Endocrinol Metab, 2015, 100(2): 697-706.
[50]
Kobayakawa T, Miyazaki A, Kanayama Y, et al. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration[J]. Mod Rheumatol, 2023, 33(1): 96-103.
[51]
Anastasilakis AD, Tsourdi E, Makras P, et al. Bone disease following solid organ transplantation: a narrative review and recommendations for management from the European Calcified Tissue Society[J]. Bone, 2019, 127: 401-418.
[52]
Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial[J]. Arthritis Rheum, 2009, 60(11): 3346-3355.
[53]
Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis[J]. Osteoporos Int, 2012, 23(12): 2769-2774.
2024年第45卷第5期
14
0
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.05.004
  • 接收时间:2024-03-09
  • 首发时间:2026-11-17
  • 出版时间:2024-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-03-09
基金
作者信息
    绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川 绵阳 621000

通讯作者:

陈静,主任药师,研究方向:药理学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.05.004
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏